AFFILIATIONS
1 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
2 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
3 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
4 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
5 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
6 The Pakistan Kidney and Liver Institute and Research Center, Lahore, Punjab, Pakistan
7 Fred Hutch Center For Community Health Promotion, Sunnyside, Washington, United States
8 King Hussien Cancer Center, Amman, Jordan, The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States
9 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
10 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
11 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
12 H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, Tampa, Florida, United States, The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States
13 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
14 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
ABSTRACT
Background:
Fludarabine/total body irradiation (Flu/TBI) has increasingly replaced cyclophosphamide/total body irradiation (Cy/TBI) as myeloablative conditioning for allogeneic hematopoietic cell transplantation (allo-HCT). Comparative data in adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) receiving post-transplant cyclophosphamide (PTCy) remain limited. We compared survival and transplant outcomes between Flu/TBI and Cy/TBI in this population.
Methods:
We performed a retrospective cohort study of AYA patients with ALL undergoing first myeloablative allo-HCT with PTCy using the Center for International Blood and Marrow Transplant Research (CIBMTR) registry (year 2013–2021, P-6144 dataset). Patients received either Cy/TBI or Flu/TBI. The primary endpoint was overall survival (OS). Secondary endpoints included relapse-free survival (RFS), GVHD-free/relapse-free survival (GRFS), chronic GVHD requiring systemic immunosuppressive therapy (IST), relapse, and non-relapse mortality (NRM). Kaplan-Meier methods were used for time-to-event analyses. Multivariable Cox proportional hazards models adjusted for age, graft source, year of transplantation, disease status, Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI), Karnofsky performance status, and donor type. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated. Statistical analyses were performed using Stata 18. A two-sided p-value <0.05 was considered statistically significant.
Results:
A total of 397 patients were included: 49 (12.3%) received Cy/TBI and 348 (87.7%) received Flu/TBI. Flu/TBI recipients were older (median age 26 vs 22 years; p=0.001), more frequently male (64.7% vs 53.1%; p=0.115), more often transplanted in CR1 (62.6% vs 42.9%; p=0.074), and far more likely to receive peripheral blood grafts (81.3% vs 42.9%; p<0.001). Cy/TBI patients had a higher proportion of pediatric Disease Risk Index classification (28.6% vs 7.8%; p<0.001) and more bone marrow grafts. KPS 90–100 was 70.4% vs 61.2% (p=0.361), HCT-CI distribution was similar (p=0.239), and ethnicity (Hispanic/Latino 39.9% vs 36.7%; p=0.425), race, donor type (predominantly haploidentical; p=0.607), CMV serostatus, and donor–recipient sex match did not differ significantly. Flu/TBI transplants were more common in later years (2019–2021; p<0.001). Unadjusted rates of grade II–IV acute GVHD (25.9% vs 20.4%; p=0.494), grade III–IV acute GVHD (6.3% vs 8.2%; p=0.509), chronic GVHD (41.7% vs 38.8%; p=0.922), chronic GVHD requiring IST (32.5% vs 30.6%; p=0.958), relapse (19.3% vs 20.4%; p=0.274), and NRM (12.6% vs 6.1%; p=0.140) were comparable. At 2 years, OS was similar (76.9% vs 76.6%; log-rank p=0.772), as were RFS (70.9% vs 70.5%; p=0.870), GRFS (39.6% vs 39.1%; p=0.655), and freedom from chronic GVHD requiring IST (63.7% vs 65.3%; p=0.632). After multivariable adjustment, Flu/TBI was not associated with inferior OS (HR 1.47, 95% CI 0.79–2.72; p=0.221), RFS (HR 1.49, 95% CI 0.79–2.83; p=0.218), or GRFS (HR 1.40, 95% CI 0.88–2.22; p=0.156).
Conclusions:
Among adolescents and young adults patients with ALL undergoing myeloablative allo-HCT with PTCy, Flu/TBI demonstrated survival and GVHD outcomes comparable to Cy/TBI after adjustment for baseline differences between groups. Despite the predominance of Flu/TBI use in this contemporary cohort, these findings support Flu/TBI as an effective myeloablative conditioning platform with potential advantages in regimen tolerability.